Neoadjuvant therapy invasive bladder cancer pitfalls clear transitional-cell tumors bladder therapy absence controlled trials impact repeated transurethral resections effect chemotherapy trials neoadjuvant therapy standard addition chemotherapy agents combination available drugs addition hematopoietic growth factors granulocyte colony-stimulating factor granulocyte-macrophage colony-stimulating factor toxicity permit dose intensification attempt overall response rates fruitful avenues clinical research cisplatin-based chemotherapy impact bladder cancer testicular cancer initial results wall demonstration urothelial tumors list responsive tumors urologic radiologic medical oncologists efforts controlled studies integrated approaches 